|Scientists from Emory University School of Medicine, along with Emory technology transfer leaders, will join a large Georgia delegation headed to the 2008 BIO International Convention in San Diego, June 17-20. The BIO convention, called "the global event for biotechnology," is expected to attract more than 20,000 bioscience professionals from more than 70 nations. Governor Sonny Perdue will promote Georgia as a premier destination for bioscience companies and will invite the global bioscience community to Atlanta next year when it hosts the 2009 BIO International Convention. This year's convention will focus on global health, sustainable agriculture and international business issues, with a focus on the promise of biotech innovation to heal, fuel and feed the world.
Emory scientists will play a prominent role in panel sessions at the BIO convention. Richard W. Compans, PhD, professor of microbiology and immunology and director of Emory's Influenza Pathogenesis and Immunology Research Center, will discuss efforts to prepare for the next flu pandemic.
Walter A. Orenstein, MD, associate director of the Emory Vaccine Center and a professor of medicine and pediatrics at Emory School of Medicine, will lead a panel on "Antibiotic-Resistant Staph Infections: Challenges and Progress," with participation from Henry M. Blumberg, MD, Emory professor of medicine and hospital epidemiologist at Grady Memorial Hospital.
Collin J. Weber, MD, professor of surgery in Emory University School of Medicine, will lead a panel on "Diabetes Treatment: Advances in Cell-Based Therapies."
Todd Sherer, PhD, director of the Emory University Office of Technology Transfer and president, Emtech Biotechnology Development, Inc., will attend the BIO convention to promote Emory's national leadership in guiding university-discovered technologies through the complex process of patenting and licensing and into the marketplace.
"Emory's technology transfer program has one of the most robust product pipelines of any university in the country," says Sherer. "Our program has resulted in 16 licensed therapeutic products, including the world's leading AIDS drugs, and 38 additional products in various stages of drug discovery, clinical development or regulatory approval. Forty-three start-up companies have been formed from Emory research discoveries."
Georgia Bio, the state's BIO affiliate and local host organization for the 2009 BIO Convention in Atlanta, is partnering with the Georgia Department of Economic Development and the Atlanta Development Authority to showcase the state's leadership in biotechnology and the life sciences, setting the stage for next year's convention in Atlanta.
For more information about the 2008 BIO convention, visit http://www.bio2008.org For more information about technology transfer at Emory, visit http://www.ott.emory.edu